Ironing out MAFLD: Therapeutic targeting of liver ferroptosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39357507.
- Also identified by DOI 10.1016/j.cmet.2024.09.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with iron metabolism disorders and ferroptosis, but the mechanisms underlying this association remain unclear. Fudi Wang's group<sup>1</sup> used animal models, human cohorts, and multi-omics data to demonstrate the role of iron imbalance in MAFLD and the therapeutic potential of the iron chelator FerroTerminator 1 (FOT1).
Medical subject headings
- Ferroptosis
- Iron
- Liver